Preparation, quality control, and absorbed dose estimation of 89Zr-DFO-Cetuximab for imaging of EGFR-expressing tumors
In this study,89Zr-DFO-Cetuximab was prepared under the optimized conditions with a radiochemical purity > 99%, and a specific activity of 185 GBq g−1. Cellular studies on EGFR + SW480 colon cancer and EGFR-CHO cell lines were performed, indicating the remarkable capability of89Zr-DFO-Cetuximab for binding to the low EGFR-expressing cells. High accumulation was observed in tumors of nude mice-bearing SW480 cell lines. Human absorbed dose estimation showed the liver receives the highest absorbed dose (0.94 mGy MBq−1). This radiopharmaceutical is the suitable PET agent for imaging of EGFR-expressing tumors at 72 –120 h after injection.
Source: Journal of Radioanalytical and Nuclear Chemistry - Category: Nuclear Medicine Source Type: research
More News: Cancer | Cancer & Oncology | Chemistry | Colon Cancer | Colorectal Cancer | Erbitux | Liver | Nuclear Medicine | Study | Urology & Nephrology